EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients

Marisol Huerta, Jorge Martín-Arana, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Blanca García-Micó, Belén Martínez-Castedo, Fabián Robledo-Yagüe, Daniel G Camblor, Tania Fleitas, Miguel García Bartolomé, Clara Alfaro-Cervelló, Marina Garcés-Albir und 10 weitere

Translational Research · 2024-09 · 271 · 105-115

DOI: 10.1016/j.trsl.2024.05.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2024-09. Verfasst von Marisol Huerta und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos I…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Exome Sequencing, Pancreatic Neoplasms, Disease Progression. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding progression mechanisms and developing new targeted therapies is imperative in pancreatic ductal adenocarcinoma (PDAC). In this study, 80 metastatic PDAC patients were prospectively recruited and divided into discovery (n=37) and validation (n=43) cohorts. Tumor and plasma samples taken at diagnosis were pair analyzed using whole exome sequencing (WES) in patients belonging to the discovery cohort alone. The variant allele frequency (VAF) of KRAS mutations was measured by ddPCR in plasma at baseline and response assessment in all patients. Plasma WES identified at least one pathogenic variant across the cohort, uncovering oncogenic mechanisms, DNA repair, microsatellite instability, and alterations in the TGFb pathway. Interestingly, actionable mutations were mostly found in plasma rather than tissue. Patients with shorter survival showed enrichment in cellular organization regulatory pathways. Through WES we could identify a specific molecular profile of patients with liver metastasis, which exhibited exclusive mutations in genes related to the adaptive immune response pathway, highlighting the importance of the immune system in liver metastasis development. Moreover, KRAS mutations in plasma (both at diagnosis and persistent at follow-up) correlated with shorter progression free survival (PFS). Patients presenting a reduction of over 84.75 % in KRAS VAF at response assessment had similar PFS to KRAS-negative patients. Overall, plasma WES reveals molecular profiles indicative of rapid progression, potentially actionable targets, and associations between adaptive immune response pathway alterations and liver tropism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalExome SequencingPancreatic NeoplasmsDisease ProgressionCirculating Tumor DNAHumansMaleFemaleMiddle AgedAgedMutationNeoplasm MetastasisProto-Oncogene Proteins p21(ras)Adult

Stichwörter der Autor:innen

Organ tropismPancreatic adenocarcinomaTargeted therapyWESctDNA

Substanzen

Circulating Tumor DNAProto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.
  • Cancer Evolution and Genome Instability Laboratory, University College London Cancer Institute, London, UK.
  • Biostatistics Unit, INCLIVA Biomedical Research Institute, University of Valencia, Spain.
  • Bioinformatics Unit, INCLIVA Biomedical Research Institute, University of Valencia, Spain.
  • Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Department of Pathology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.

Zitieren

APA

Huerta, M., Martín-Arana, J., Gimeno-Valiente, F., Carbonell-Asins, J. A., García-Micó, B., Martínez-Castedo, B., Robledo-Yagüe, F., Camblor, D. G., Fleitas, T., García Bartolomé, M., Alfaro-Cervelló, C., Garcés-Albir, M., Dorcaratto, D., Muñoz-Forner, E., Seguí, V., Mora-Oliver, I., Gambardella, V., Roselló, S., Sabater, L., …, & Tarazona, N. (2024). ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients. Translational Research, 271, 105-115. https://doi.org/10.1016/j.trsl.2024.05.003

Vancouver

Huerta M, Martín-Arana J, Gimeno-Valiente F, Carbonell-Asins JA, García-Micó B, Martínez-Castedo B, et al. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients. Translational Research. 2024;271:105-115. doi:10.1016/j.trsl.2024.05.003

BibTeX
@article{Huerta2024,
  author = {Huerta, Marisol and Martín-Arana, Jorge and Gimeno-Valiente, Francisco and Carbonell-Asins, Juan Antonio and García-Micó, Blanca and Martínez-Castedo, Belén and Robledo-Yagüe, Fabián and Camblor, Daniel G and Fleitas, Tania and García Bartolomé, Miguel and Alfaro-Cervelló, Clara and Garcés-Albir, Marina and Dorcaratto, Dimitri and Muñoz-Forner, Elena and Seguí, Víctor and Mora-Oliver, Isabel and Gambardella, Valentina and Roselló, Susana and Sabater, Luis and Roda, Desamparados and Cervantes, Andrés and Tarazona, Noelia},
  title = {ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients},
  journal = {Translational Research},
  year = {2024},
  volume = {271},
  pages = {105--115},
  doi = {10.1016/j.trsl.2024.05.003}
}
Kostenlos starten →